TWI647224B - 激酶抑制劑化合物的多晶型、含其的藥物組合物及其製備方法和應用 - Google Patents
激酶抑制劑化合物的多晶型、含其的藥物組合物及其製備方法和應用 Download PDFInfo
- Publication number
- TWI647224B TWI647224B TW106133830A TW106133830A TWI647224B TW I647224 B TWI647224 B TW I647224B TW 106133830 A TW106133830 A TW 106133830A TW 106133830 A TW106133830 A TW 106133830A TW I647224 B TWI647224 B TW I647224B
- Authority
- TW
- Taiwan
- Prior art keywords
- methanol
- solvent
- compound
- crystal form
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610866253.6 | 2016-09-29 | ||
| ??201610866253.6 | 2016-09-29 | ||
| CN201610866253 | 2016-09-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201815785A TW201815785A (zh) | 2018-05-01 |
| TWI647224B true TWI647224B (zh) | 2019-01-11 |
Family
ID=61763329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106133830A TWI647224B (zh) | 2016-09-29 | 2017-09-29 | 激酶抑制劑化合物的多晶型、含其的藥物組合物及其製備方法和應用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11053224B2 (enExample) |
| EP (1) | EP3502105B8 (enExample) |
| JP (2) | JP7253491B2 (enExample) |
| KR (1) | KR102289684B1 (enExample) |
| CN (1) | CN108884080B (enExample) |
| AU (1) | AU2017336889B2 (enExample) |
| CA (2) | CA3035124C (enExample) |
| EA (1) | EA201990688A1 (enExample) |
| ES (1) | ES2914294T3 (enExample) |
| IL (2) | IL265266B2 (enExample) |
| MY (1) | MY194364A (enExample) |
| PH (1) | PH12019500681A1 (enExample) |
| PL (1) | PL3502105T3 (enExample) |
| SG (1) | SG11201901962QA (enExample) |
| TW (1) | TWI647224B (enExample) |
| WO (1) | WO2018059556A1 (enExample) |
| ZA (1) | ZA201901717B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901962QA (en) * | 2016-09-29 | 2019-04-29 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
| SI4210682T1 (sl) | 2020-09-14 | 2026-07-31 | EyePoint, Inc. | Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda |
| CN117157294A (zh) * | 2021-03-16 | 2023-12-01 | 怡诺安有限公司 | 作为蛋白激酶抑制剂的杂环化合物的结晶形式 |
| JP7138982B1 (ja) | 2021-09-24 | 2022-09-20 | 東海物産株式会社 | アンセリンの結晶及びその製造方法 |
| IL315331A (en) | 2022-03-11 | 2024-10-01 | Eyepoint Pharmaceuticals Inc | A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye |
| US20250186398A1 (en) | 2022-03-11 | 2025-06-12 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
| TW202345804A (zh) | 2022-03-11 | 2023-12-01 | 美商視點製藥有限公司 | 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法 |
| JP2026520094A (ja) | 2023-04-11 | 2026-06-22 | オキュラ セラピューティクス，インコーポレイテッド | アキシチニブ多形ｉｖを含む眼科インプラント |
| CN117143083B (zh) * | 2023-08-30 | 2026-02-27 | 沈阳药科大学 | VEGFR抑制剂Vorolanib的合成方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003031438A1 (en) * | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| CN101553482A (zh) * | 2006-09-15 | 2009-10-07 | 艾科睿制药公司 | 激酶抑制剂化合物 |
| CN102272124A (zh) * | 2008-11-13 | 2011-12-07 | 力奇制药公司 | 舒尼替尼苹果酸盐的新晶形 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110026367A1 (en) * | 2007-05-07 | 2011-02-03 | Baumer Electric Ag | Acoustic Transducer |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| WO2009128083A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| CN102066362B (zh) | 2008-05-23 | 2014-07-30 | 上海医药工业研究院 | 二氢吲哚酮衍生物 |
| EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| SG11201901962QA (en) * | 2016-09-29 | 2019-04-29 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
-
2017
- 2017-09-29 SG SG11201901962QA patent/SG11201901962QA/en unknown
- 2017-09-29 WO PCT/CN2017/104506 patent/WO2018059556A1/zh not_active Ceased
- 2017-09-29 KR KR1020197008752A patent/KR102289684B1/ko active Active
- 2017-09-29 CN CN201780008042.1A patent/CN108884080B/zh active Active
- 2017-09-29 US US16/338,357 patent/US11053224B2/en active Active
- 2017-09-29 IL IL265266A patent/IL265266B2/en unknown
- 2017-09-29 CA CA3035124A patent/CA3035124C/en active Active
- 2017-09-29 PL PL17855006T patent/PL3502105T3/pl unknown
- 2017-09-29 EP EP17855006.7A patent/EP3502105B8/en active Active
- 2017-09-29 TW TW106133830A patent/TWI647224B/zh active
- 2017-09-29 MY MYPI2019000596A patent/MY194364A/en unknown
- 2017-09-29 CA CA3253105A patent/CA3253105A1/en active Pending
- 2017-09-29 AU AU2017336889A patent/AU2017336889B2/en active Active
- 2017-09-29 EA EA201990688A patent/EA201990688A1/ru unknown
- 2017-09-29 JP JP2019538551A patent/JP7253491B2/ja active Active
- 2017-09-29 ES ES17855006T patent/ES2914294T3/es active Active
-
2019
- 2019-03-19 ZA ZA201901717A patent/ZA201901717B/en unknown
- 2019-03-28 PH PH12019500681A patent/PH12019500681A1/en unknown
-
2021
- 2021-06-15 US US17/348,482 patent/US12209080B2/en active Active
-
2023
- 2023-03-28 JP JP2023052465A patent/JP7763203B2/ja active Active
-
2024
- 2024-03-20 IL IL311631A patent/IL311631B2/en unknown
-
2025
- 2025-01-27 US US19/038,129 patent/US20250188063A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003031438A1 (en) * | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| CN101553482A (zh) * | 2006-09-15 | 2009-10-07 | 艾科睿制药公司 | 激酶抑制剂化合物 |
| CN102272124A (zh) * | 2008-11-13 | 2011-12-07 | 力奇制药公司 | 舒尼替尼苹果酸盐的新晶形 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7763203B2 (ja) | キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 | |
| JP6756617B2 (ja) | Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法 | |
| JP2017505796A5 (enExample) | ||
| CN110621662B (zh) | 一种盐的结晶性固体形式、制备工艺和使用方法 | |
| JP2021529783A (ja) | Ｒａｄ１９０１−２ｈｃｌの多形形態 | |
| KR20140047483A (ko) | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 | |
| US9884856B2 (en) | Crystal form of Dabrafenib mesylate and preparation method thereof | |
| CN112047893A (zh) | 吉非替尼与水杨酸共晶体 | |
| WO2024104268A1 (zh) | 艾拉司群二盐酸盐的共晶及其制备方法和用途 | |
| HK1257194B (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| BR112019006023B1 (pt) | Forma cristalina, método de preparação da forma cristalina, e, composição farmacêutica | |
| WO2023143321A1 (zh) | 他伐帕敦的晶型及其制备方法和用途 | |
| TW202440585A (zh) | MDM2-p53抑制劑之晶型及醫藥組合物 | |
| CN121487928A (zh) | (3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新固体形式 | |
| AU2021231396A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine | |
| HK40020497B (en) | Crystalline solid forms of salts, processes for making, and methods of use |